Share Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

Copy link

December 01, 2025

Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

1 hour 2 minutes

Please visit answersincme.com/860/99224979-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the latest data on emerging B7-H3–directed antibody–drug conjugates (ADCs) for the treatment previously treated extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Specify how B7-H3 overexpression is relevant to ES-SCLC prognosis and treatment; Interpret the clinical evidence for emerging B7H3–directed ADCs in patients with previously treated ES-SCLC; and Translate current evidence and clinical considerations for B7-H3–targeted ADCs into treatment algorithms for patients with ES-SCLC.

...more